Journal of cardiovascular electrophysiology · 2025
Impact of Immunosuppressive Drugs on Patients With Percutaneous Left Atrial Appendage Occlusion.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Togashi Daisuke, Ellis Christopher R, Yoneda Zachary T, Gregory Jackon G, Uetake Shunsuke, Alahwany Salah H, Baker Michael T, Kanagasundram Arvindh N
Аннотация
INTRODUCTION: Percutaneous left atrial appendage closure (LAAC) reduces the risk of thromboembolic stroke in patients with non-valvular atrial fibrillation who cannot tolerate long-term oral anticoagulation. However, outcomes after LAAC in patients requiring chronic immunosuppressive therapy (IMS) remain unknown. This study aimed to investigate the perioperative and long-term outcomes of percutaneous LAAC in patients receiving chronic IMS.
METHODS AND RESULTS: Patients who underwent LAAC were retrospectively evaluated according to the presence of long-term IMS therapy. Perioperative complications, clinical outcomes, and device follow-up characteristics were evaluated. From November 2017 to March 2023, a total of 1172 patients who underwent LAAC were included (69.3% male, 74.8 years), of whom 74 were taking IMS. The most common reasons for IMS use were rheumatoid arthritis (50.0%), followed by kidney transplantation (17.6%). There were no significant differences in intraoperative complications between the IMS group and the non-IMS group. (1.4% vs. 1.3%, p = 0.943). During 617 [IQR: 373-1046] days, the incidence of systemic infections was higher in the IMS group (25.0% vs. 6.1%, p < 0.001). There were no significant differences in peri-device leak (PDL) or device-related thrombus, but the IMS group had a lower percentage of patients with improvement of PDL during follow-up (8.3% vs. 50.0%, p = 0.003).
CONCLUSION: Successful LAAC in patients on IMS was achieved without increasing perioperative complications. Patients on chronic IMS did have an increased occurrence of systemic infections during long-term follow-up. The presence of IMS use was negatively associated with PDL improvement during follow-up.
METHODS AND RESULTS: Patients who underwent LAAC were retrospectively evaluated according to the presence of long-term IMS therapy. Perioperative complications, clinical outcomes, and device follow-up characteristics were evaluated. From November 2017 to March 2023, a total of 1172 patients who underwent LAAC were included (69.3% male, 74.8 years), of whom 74 were taking IMS. The most common reasons for IMS use were rheumatoid arthritis (50.0%), followed by kidney transplantation (17.6%). There were no significant differences in intraoperative complications between the IMS group and the non-IMS group. (1.4% vs. 1.3%, p = 0.943). During 617 [IQR: 373-1046] days, the incidence of systemic infections was higher in the IMS group (25.0% vs. 6.1%, p < 0.001). There were no significant differences in peri-device leak (PDL) or device-related thrombus, but the IMS group had a lower percentage of patients with improvement of PDL during follow-up (8.3% vs. 50.0%, p = 0.003).
CONCLUSION: Successful LAAC in patients on IMS was achieved without increasing perioperative complications. Patients on chronic IMS did have an increased occurrence of systemic infections during long-term follow-up. The presence of IMS use was negatively associated with PDL improvement during follow-up.